Mologen AG, a German based biotechnology company, has obtained medicine status for their cell-based gene therapy against kidney cancer. This status was granted by Innovation Task Force (ITF), a committee of the European Medicines Evaluation Agency (EMEA), a company release said.
Other than the company's proprietary DNA molecules, MIDGE and dSLIM, cells are not a prior regarded as medicine, and therefore, this notification is of utmost importance. It is a major step forward for further clinical development of this cancer therapy in Europe, the release added.
The Company employs for this type of cancer therapy human cells derived from its proprietary master cell banks. Such cells are several fold gene modified with MIDGE vectors and immunomodulated by dSLIM.
Mologen uses its proprietary DNA technologies to create and develop treatments for high-unmet-need illnesses. The main focuses are the unique and patented MIDGE and dSLIM technologies. Based on these platforms, Mologen is developing DNA-based vaccines and therapeutics to prevent or cure a wide range of diseases. Going to public in 1998, Mologen was one of the first German biotechnology companies to be floated on the stock exchange.